Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

7.460 +0.130 (+1.77%)
Streaming Delayed Price Updated: 1:38 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,853
Open 7.460
Bid (Size) 7.350 (200)
Ask (Size) 7.460 (100)
Prev. Close 7.330
Today's Range 6.850 - 7.475
52wk Range 6.420 - 22.90
Shares Outstanding 16,008,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
Via ACCESS Newswire
News headline image
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
Via ACCESS Newswire

Performance

YTD
+1.8%
+1.8%
1 Month
-26.7%
-26.7%
3 Month
-44.9%
-44.9%
6 Month
-42.4%
-42.4%
1 Year
-54.4%
-54.4%

More News

Read More
News headline image
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
Via ACCESS Newswire
News headline image
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
Via ACCESS Newswire
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
News headline image
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
From Cadrenal Therapeutics
Via Business Wire
News headline image
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Cadrenal Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cadrenal Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cadrenal Therapeutics, Inc. - Common Stock trade on?
Cadrenal Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock?
The ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock is CVKD on the Nasdaq Stock Market
What is the current price of Cadrenal Therapeutics, Inc. - Common Stock?
The current price of Cadrenal Therapeutics, Inc. - Common Stock is 7.460
When was Cadrenal Therapeutics, Inc. - Common Stock last traded?
The last trade of Cadrenal Therapeutics, Inc. - Common Stock was at 01/05/26 01:38 PM ET
What is the market capitalization of Cadrenal Therapeutics, Inc. - Common Stock?
The market capitalization of Cadrenal Therapeutics, Inc. - Common Stock is 119.42M
How many shares of Cadrenal Therapeutics, Inc. - Common Stock are outstanding?
Cadrenal Therapeutics, Inc. - Common Stock has 119M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.